MacroGenics TAMARACK Phase 2 data: 6-month rPFS 69-70%, ORR up to 40.6%, but 8 treatment-related deaths

MACROGENICS INC

6-month radiographic PFS rate 69% (2.0 mg/kg) and 70% (2.7 mg/kg); median rPFS ~8.5 and 7.5 months (immature).
Confirmed ORR 20.0% (2.0 mg/kg) and 40.6% (2.7 mg/kg) among RECIST-evaluable patients.
Median 6 doses received (range 1-12); 25.6% (2.0 mg/kg) and 18.6% (2.7 mg/kg) remained on drug at data cutoff.
Grade ≥3 TEAEs: 65.6% (2.0 mg/kg) and 62.8% (2.7 mg/kg); discontinuation rates 25.6% and 38.4%.
8 fatal treatment-related AEs (5 in 2.0 mg/kg, 3 in 2.7 mg/kg) including pneumonitis and cardiac events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.